Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
August 03 2022 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators to treat pediatric and adult
liver diseases, today announced participation in the 2022 Wedbush
PacGrow Healthcare Conference August 9-10, 2022. Ron Cooper,
President and Chief Executive Officer of Albireo, will be
presenting on August 9, 2022. A replay of the webcast will be
available on-demand on the Albireo Investors page
ir.albireopharma.com. Ron and Simon Harford, Chief Financial
Officer, will host meetings with investors.
About Albireo
Albireo Pharma is a rare disease company focused on the
development of novel bile acid modulators to treat pediatric and
adult liver diseases. Albireo’s lead product, Bylvay, was approved
by the U.S. FDA as the first drug for the treatment of pruritus in
all types of progressive familial intrahepatic cholestasis (PFIC),
and in Europe, Bylvay has been approved for the treatment of
PFIC. Bylvay is also being developed to treat other rare pediatric
cholestatic liver diseases with global Phase 3 trials in Alagille
syndrome (ALGS) and biliary atresia, as well as Open-label
Extension (OLE) studies for PFIC and ALGS. The Company has also
completed a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
progressing with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024